Pharvaris N.V. Stock Price, News & Analysis

Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.

Pharvaris N.V. (PHVS) news centers on its progress as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema. Company updates frequently highlight clinical milestones for its lead candidate deucrictibant, including pivotal Phase 3 programs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

Investors following PHVS news can expect detailed announcements on clinical trial results and timelines. Recent releases describe RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, which met its primary endpoint and all secondary efficacy endpoints with statistical significance and was reported as well tolerated. Other updates cover CHAPTER-3 and CHAPTER-4, Phase 3 studies of the extended-release tablet for long-term prophylaxis of HAE attacks, and CHAPTER-1 Phase 2 data showing sustained reductions in attack rates over long-term treatment.

Pharvaris news also includes information on the CREAATE Phase 3 study in AAE-C1INH, presentations of deucrictibant data at major medical congresses, and summaries of biomarker work such as the kinin assay being clinically validated to characterize bradykinin-mediated angioedema. Financial and corporate updates, including quarterly results, cash runway commentary, and details of public offerings of ordinary shares and pre-funded warrants, are furnished through press releases and Form 6-K filings.

For readers tracking PHVS, this news stream provides insight into the advancement of deucrictibant’s prophylactic and on-demand indications, regulatory filing plans such as the preparation of marketing authorization applications, and the company’s broader efforts in bradykinin-mediated diseases.